LVW Advisors LLC Acquires New Position in Moderna, Inc. (NASDAQ:MRNA)

LVW Advisors LLC purchased a new position in Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 10,500 shares of the company's stock, valued at approximately $298,000.

A number of other hedge funds have also made changes to their positions in the stock. Blue Trust Inc. raised its stake in Moderna by 53.1% during the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company's stock worth $47,000 after acquiring an additional 388 shares during the period. Caprock Group LLC bought a new stake in shares of Moderna in the 4th quarter worth approximately $203,000. Tokio Marine Asset Management Co. Ltd. grew its stake in Moderna by 15.9% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 12,499 shares of the company's stock worth $520,000 after buying an additional 1,715 shares during the last quarter. Spire Wealth Management increased its position in Moderna by 2,150.4% in the fourth quarter. Spire Wealth Management now owns 23,224 shares of the company's stock worth $966,000 after buying an additional 22,192 shares during the period. Finally, Greenleaf Trust lifted its stake in Moderna by 49.6% in the fourth quarter. Greenleaf Trust now owns 5,244 shares of the company's stock valued at $218,000 after buying an additional 1,739 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna Stock Down 4.2%

Shares of Moderna stock traded down $1.15 during trading on Thursday, hitting $26.12. The stock had a trading volume of 9,777,454 shares, compared to its average volume of 8,245,710. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $158.82. The stock has a 50 day simple moving average of $26.23 and a 200 day simple moving average of $33.71. The company has a market capitalization of $10.10 billion, a PE ratio of -2.81 and a beta of 1.86.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, topping the consensus estimate of ($2.92) by $0.40. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The business had revenue of $108.00 million during the quarter, compared to analysts' expectations of $130.35 million. During the same quarter last year, the firm posted ($3.07) earnings per share. Moderna's revenue was down 35.3% compared to the same quarter last year. As a group, equities analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on MRNA shares. Bank of America dropped their price objective on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a report on Tuesday, February 11th. Morgan Stanley dropped their price target on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 9th. Royal Bank of Canada reduced their price objective on Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. William Blair reissued a "market perform" rating on shares of Moderna in a report on Monday. Finally, Barclays cut their target price on Moderna from $45.00 to $40.00 and set an "equal weight" rating on the stock in a research note on Friday, May 2nd. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Moderna currently has an average rating of "Hold" and an average target price of $53.58.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.